TG Therapeutics Inc TGTX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if TGTX is a good fit for your portfolio.
News
-
Global Multiple Sclerosis Drugs Market Size Projected to Reach $38 Billion By 2032 as Demand on R&D for Developing Innovative Drugs Rises
-
TG Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
-
TG Therapeutics to Participate in the Jefferies Global Healthcare Conference
-
TG Therapeutics Announces Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the 2024 Consortium of Multiple Sclerosis Centers Annual Meeting
-
TG Therapeutics Announces Schedule of Upcoming Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the 2024 Consortium of Multiple Sclerosis Centers Annual Meeting
-
TG Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
-
TG Therapeutics to Host Conference Call on First Quarter 2024 Financial Results and Business Update
-
TG Therapeutics agrees to purchase a global license to a Car T cell therapy program for autoimmune diseases
Trading Information
- Previous Close Price
- $19.98
- Day Range
- $19.98–20.80
- 52-Week Range
- $6.46–23.12
- Bid/Ask
- $20.59 / $20.80
- Market Cap
- $3.18 Bil
- Volume/Avg
- 2.0 Mil / 3.1 Mil
Key Statistics
- Price/Earnings (Normalized)
- 20.55
- Price/Sales
- 10.66
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). and the company is developing TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders which are under Phase 1 trial.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 264
- Website
- https://www.tgtherapeutics.com
Comparables
Valuation
Metric
|
TGTX
|
CTIC
|
ALVR
|
---|---|---|---|
Price/Earnings (Normalized) | 20.55 | — | — |
Price/Book Value | 19.85 | — | 0.75 |
Price/Sales | 10.66 | 14.71 | — |
Price/Cash Flow | 37.30 | — | — |
Price/Earnings
TGTX
CTIC
ALVR
Financial Strength
Metric
|
TGTX
|
CTIC
|
ALVR
|
---|---|---|---|
Quick Ratio | 2.76 | 1.20 | 18.38 |
Current Ratio | 3.62 | 1.27 | 18.48 |
Interest Coverage | 4.45 | −3.20 | — |
Quick Ratio
TGTX
CTIC
ALVR
Profitability
Metric
|
TGTX
|
CTIC
|
ALVR
|
---|---|---|---|
Return on Assets (Normalized) | 27.97% | −46.52% | −52.15% |
Return on Equity (Normalized) | 73.42% | — | −65.46% |
Return on Invested Capital (Normalized) | 42.25% | −143.40% | −59.04% |
Return on Assets
TGTX
CTIC
ALVR
Biotechnology Industry Comparables
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|---|
Novo Nordisk A/S ADR
NVO
| Xxmzwhtjm | Hyvw | $565.6 Bil | |||
Vertex Pharmaceuticals Inc
VRTX
| Fnzzzmqqf | Kqxqgjf | $127.8 Bil | |||
Regeneron Pharmaceuticals Inc
REGN
| Yyyydxbt | Hzdmdrd | $118.7 Bil | |||
Moderna Inc
MRNA
| Smxlbfnrd | Cfls | $46.8 Bil | |||
Alnylam Pharmaceuticals Inc
ALNY
| Kfbjgjqh | Kjjvp | $29.7 Bil | |||
argenx SE ADR
ARGX
| Zknmhrcd | Jrpwt | $29.3 Bil | |||
BioNTech SE ADR
BNTX
| Mlrmmswts | Dzycv | $20.7 Bil | |||
Biomarin Pharmaceutical Inc
BMRN
| Nxvsbzhg | Wghnm | $16.1 Bil | |||
United Therapeutics Corp
UTHR
| Yztxhztrf | Pfcy | $15.0 Bil | |||
Incyte Corp
INCY
| Pqtzjgqc | Ndlxmp | $13.5 Bil |